个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin as first-line treatment for Chinese patients with ovarian cancer: A multi-center, randomized, open-label trial

| 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP) ◇ 自然指数

作者：
Shen, Yuanming[1] * ; Kong, Beihua[2] ; Xia, Bairong[3] ; Wang, Fei[4] ; Yin, Rutie[5] ; Li, Qingshui[6] ; Yue, Ying[7] ; Kang, Shan[8] ;
机构： [1]Zhejiang Univ, Sch Med, Womens Hosp, Hangzhou, Zhejiang, Peoples R China [2]Shandong Univ, Qilu Hosp, Jinan, Peoples R China [3]Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp 1, Hefei, Peoples R China [4]Shandong Prov Hosp, Jinan, Peoples R China [5]Sichuan Univ, West China Univ Hosp 2, Chengdu, Sichuan, Peoples R China [6]Shandong Canc Hosp & Inst, Jinan, Peoples R China [7]Jilin Univ, Affiliated Hosp 1, Changchun, Peoples R China [8]Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China [9]Hebei Tumor Hosp, Shijiazhuang, Hebei, Peoples R China [10]Guizhou Med Univ, Affiliated Canc Hosp, Guiyang, Guizhou, Peoples R China [11]Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China [12]Chinese Peoples Liberat Army Gen Hosp, Dept Gynecol & Obstet, Beijing, Peoples R China [13]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China [14]Tianjin Cent Hosp Gynecol & Obstet, Tianjin, Peoples R China [15]Hebei Med Univ, Hosp 2, Shijiazhuang, Hebei, Peoples R China [16]Zhengzhou Univ, Affiliated Hosital 1, Zhengzhou, Peoples R China [17]Hebei Gen Hosp, Shijiazhuang, Hebei, Peoples R China [18]Maternal & Child Hlth Hosp Jiangxi Prov, Nanchang, Jiangxi, Peoples R China [19]Harbin Med Univ, Canc Hosp, Harbin, Heilongjiang, Peoples R China [20]Jiangsu Prov Hosp, Nanjing, Peoples R China [21]Zhejiang Univ, Womens Hosp, Sch Med, Hangzhou, Peoples R China
出处：
ISSN：
基金：
CSPC Ouyi Pharmaceutical Group Co., Ltd
语种：
外文
被引次数：
WOS：
中科院分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY
最新[2024]版：
Q1 ONCOLOGY

影响因子： 最新[2024版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版] 出版后一年[2024版]

第一作者：
第一作者机构： [1]Zhejiang Univ, Sch Med, Womens Hosp, Hangzhou, Zhejiang, Peoples R China
推荐引用方式(GB/T 7714)：
Shen Yuanming,Kong Beihua,Xia Bairong,et al.Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin as first-line treatment for Chinese patients with ovarian cancer: A multi-center, randomized, open-label trial[J].JOURNAL OF CLINICAL ONCOLOGY.2023,41(16):
APA：
Shen, Yuanming,Kong, Beihua,Xia, Bairong,Wang, Fei,Yin, Rutie...&Kang, Shan.(2023).Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin as first-line treatment for Chinese patients with ovarian cancer: A multi-center, randomized, open-label trial.JOURNAL OF CLINICAL ONCOLOGY,41,(16)
MLA：
Shen, Yuanming,et al."Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin as first-line treatment for Chinese patients with ovarian cancer: A multi-center, randomized, open-label trial".JOURNAL OF CLINICAL ONCOLOGY 41..16(2023)

资源点击量：42329 今日访问量：0 总访问量：1365 更新日期：2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号